Syngene International Ltd reports Q2 FY27 revenue of ₹833 crore and secures its first manufacturing agreement for the U.S. Bayview biologics facility
- Revenue rose 13% sequentially but declined 9% year on year; operating EBITDA margin was 18%, up 6 percentage points sequentially and down about 4 points year on year.
- Net profit after exceptional items was ₹32 crore, versus a ₹9 crore loss in Q1 FY27 and ₹67 crore profit in Q2 FY26.
- Q2 included ₹6 crore of after-tax termination-benefit expenses as an exceptional item.
Original Filing: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=316c4f90-c29d-4699-af57-684b346bd9b6.pdf